Hyaluronic Acid-Bilirubin Nanoparticles as a Tumor Microenvironment Reactive Oxygen Species-Responsive Nanomedicine for Targeted Cancer Therapy
Seonju Lee,Seon Ah Lee,Jongyoon Shinn,Yonghyun Lee
DOI: https://doi.org/10.2147/ijn.s460468
IF: 7.033
2024-05-28
International Journal of Nanomedicine
Abstract:Seonju Lee, Seon Ah Lee, Jongyoon Shinn, Yonghyun Lee College of Pharmacy, Ewha Womans University, Seoul, 03760, South Korea Correspondence: Yonghyun Lee, College of Pharmacy, Ewha Womans University, Seoul, 03760, South Korea, Email Introduction: The tumor microenvironment (TME) has attracted considerable attention as a potential therapeutic target for cancer. High levels of reactive oxygen species (ROS) in the TME may act as a stimulus for drug release. In this study, we have developed ROS-responsive hyaluronic acid-bilirubin nanoparticles (HABN) loaded with doxorubicin (DOX@HABN) for the specific delivery and release of DOX in tumor tissue. The hyaluronic acid shell of the nanoparticles acts as an active targeting ligand that can specifically bind to CD44-overexpressing tumors. The bilirubin core has intrinsic anti-cancer activity and ROS-responsive solubility change properties. Methods & Results: DOX@HABN showed the HA shell-mediated targeting ability, ROS-responsive disruption leading to ROS-mediated drug release, and synergistic anti-cancer activity against ROS-overproducing CD44-overexpressing HeLa cells. Additionally, intravenously administered HABN-Cy5.5 showed remarkable tumor-targeting ability in HeLa tumor-bearing mice with limited distribution in major organs. Finally, intravenous injection of DOX@HABN into HeLa tumor-bearing mice showed synergistic anti-tumor efficacy without noticeable side effects. Conclusion: These findings suggest that DOX@HABN has significant potential as a cancer-targeting and TME ROS-responsive nanomedicine for targeted cancer treatment. Keywords: tumor microenvironment, reactive oxygen species, hyaluronic acid-bilirubin nanomedicine, stimuli-responsive nanomedicine The tumor microenvironment (TME) can serve as a "soil" with conditions that are conducive to providing growth, survival, and metastasis of tumor cells or "seeds". Thus, the TME has a crucial role in the survival and treatment of patients with tumors. 1–3 The characteristics of the TME differ from normal tissue, such as hypoxia, mildly acidic pH, high levels of reactive oxygen species (ROS), and elevated levels of certain enzymes. 2,4–9 Among these features, the high levels of ROS generated by cancer cells and TME-associated cells such as cancer-associated fibroblasts, myeloid-derived suppressor cells, and tumor-associated macrophages have received significant attention as a stimulus for efficient drug release from ROS-responsive nanomedicines. 10–15 Although various ROS-responsive nanoparticles have been developed, most have drawbacks such as de novo -synthesized artificial material-based potential toxicity issues, slow ROS responsiveness, and/or complexity of final nano-formulations, limiting their clinical translation. 15–17 Therefore, there is a need for biocompatible ROS-responsive nanoparticles that can act rapidly with a simple formulation. 15,18 A combination of two or more anti-cancer therapeutics is a general approach in most cancer regimens. However, combining multiple anti-cancer therapeutics in a single nanoparticle increases the complexity of the nanoformulation, hindering clinical translation. 19–21 Thus, the intrinsic anti-cancer activity of a nanoparticle itself could enhance the synergistic anti-cancer activity of an encapsulated anti-cancer agent, reducing the complexity of the formulation. 22,23 Toward this goal, we used hyaluronic acid-bilirubin nanoparticles (HABN), which are biocompatible and versatile nanoparticles with a simple formulation. The bilirubin (BR) core endows HABN with two key features: 1) rapid responsiveness to ROS facilitated by the solubility changes of the hydrophobic BR core to hydrophilic biliverdin and BR oxidative products, and 2) intrinsic therapeutic efficacy attributed to the anti-cancer activity of the BR core. 24–26 Moreover, due to the CD44-targeting capacity of the hydrophilic hyaluronic acid (HA) shell, HABN has the potential to target cells that overexpress CD44. 27–30 Our previous reports have highlighted the compelling features of HABN, 27,31,32 such as gut microbiome modulation activity, intrinsic therapeutic potential against colitis, and ability to target CD44-overexpressing cells such as macrophages, tumor cells, activated hepatic stellate cells, and intestinal epithelial cells. However, the potential impact of HABN in targeting ROS-overproducing and CD44-overexpressing tumors while simultaneously demonstrating ROS-mediated drug release and intrinsic therapeutic efficacy remains unexplored. Notably, although PEGylated BR nanoparticles rely on extra components for active targeting, HABN demonstrates active targeting itself without the need for any additional components, simpl -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology